refer to descriptions included in the company's filings with the securities and exchange commission for more information about the company. the company does not intend to update and does not take responsibility for any information published on linkedin.
Company profile
Ticker
SAVA
Exchange
Website
CEO
Remi Barbier
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
PAIN THERAPEUTICS INC
SEC CIK
Corporate docs
Subsidiaries
Austin Innovation Park, LLC ...
IRS number
911911336
SAVA stock data
Latest filings (excl ownership)
8-K
Redemption Date Announced for Warrants
15 Apr 24
DEF 14A
Definitive proxy
26 Mar 24
ARS
2023 FY
Annual report to shareholders
22 Mar 24
10-K
2023 FY
Annual report
28 Feb 24
8-K
Cassava Sciences Reports Full-year 2023 Financial Results and Corporate Updates
28 Feb 24
8-K
No Decline in Cognition Scores in Patients with Mild Alzheimer's Disease Who Received Simufilam Continuously For 24 Months
7 Feb 24
CERT
Certification of approval for exchange listing
3 Jan 24
424B2
Prospectus for primary offering
3 Jan 24
8-A12B
Registration of securities on exchange
3 Jan 24
8-K
Entry into a Material Definitive Agreement
3 Jan 24
Transcripts
Latest ownership filings
4
James William Kupiec
22 Apr 24
4
Eric Schoen
17 Apr 24
SC 13G/A
VANGUARD GROUP INC
13 Feb 24
SC 13G/A
BARBIER REMI
1 Feb 24
SC 13G/A
BlackRock Inc.
26 Jan 24
4
Claude Nicaise
8 Dec 23
3
Claude Nicaise
8 Dec 23
4
Pierre Gravier
7 Dec 23
4
Robert Eugene Anderson Jr
7 Dec 23
3
Pierre Gravier
7 Dec 23
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 142.35 mm | 142.35 mm | 142.35 mm | 142.35 mm | 142.35 mm | 142.35 mm |
Cash burn (monthly) | 8.70 mm | 2.69 mm | 9.29 mm | 8.68 mm | 8.84 mm | 6.75 mm |
Cash used (since last report) | 59.39 mm | 18.39 mm | 63.47 mm | 59.25 mm | 60.40 mm | 46.12 mm |
Cash remaining | 82.96 mm | 123.96 mm | 78.88 mm | 83.10 mm | 81.95 mm | 96.23 mm |
Runway (months of cash) | 9.5 | 46.0 | 8.5 | 9.6 | 9.3 | 14.3 |
Institutional ownership, Q3 2023
29.4% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 142 |
Opened positions | 19 |
Closed positions | 24 |
Increased positions | 55 |
Reduced positions | 30 |
13F shares | Current |
---|---|
Total value | 204.66 bn |
Total shares | 12.72 mm |
Total puts | 2.53 mm |
Total calls | 2.72 mm |
Total put/call ratio | 0.9 |
Largest owners | Shares | Value |
---|---|---|
BLK Blackrock | 2.84 mm | $47.24 bn |
Vanguard | 2.27 mm | $37.75 bn |
STT State Street | 1.03 mm | $17.07 bn |
Geode Capital Management | 830.25 k | $13.82 bn |
BAC Bank Of America | 621.80 k | $10.35 bn |
Gallacher Capital Management | 577.82 k | $9.61 bn |
MS Morgan Stanley | 433.24 k | $7.21 bn |
NTRS Northern Trust | 373.63 k | $6.22 bn |
Charles Schwab Investment Management | 304.72 k | $5.07 bn |
SG Americas Securities | 276.43 k | $4.60 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
18 Apr 24 | James William Kupiec | Common Stock | Option exercise | Acquire M | No | No | 22 | 1,500 | 33.00 k | 4,000 |
18 Apr 24 | James William Kupiec | Common Stock Warrant Common Stock | Option exercise | Dispose M | No | No | 33 | 1,000 | 33.00 k | 0 |
17 Apr 24 | Eric Schoen | Common Stock | Option exercise | Acquire M | No | No | 22 | 1,500 | 33.00 k | 21,300 |
17 Apr 24 | Eric Schoen | Common Stock Warrant Common Stock | Option exercise | Dispose M | No | No | 33 | 1,000 | 33.00 k | 6,920 |
3 Jan 24 | James William Kupiec | Common Stock Warrant Common Stock | Grant | Acquire A | No | No | 33 | 1,000 | 33.00 k | 1,000 |
3 Jan 24 | Eric Schoen | Common Stock Warrant Common Stock | Grant | Acquire A | Yes | No | 33 | 800 | 26.40 k | 800 |
3 Jan 24 | Eric Schoen | Common Stock Warrant Common Stock | Grant | Acquire A | No | No | 33 | 7,920 | 261.36 k | 7,920 |
6 Dec 23 | Robert Eugene Anderson Jr | Stock Option Common Stock | Grant | Acquire A | No | No | 21.71 | 20,000 | 434.20 k | 20,000 |
News
Why JPMorgan Shares Are Trading Lower By Around 5%? Here Are Other Stocks Moving In Friday's Mid-Day Session
12 Apr 24
Cassava Sciences Completes Interim Safety Review Of Oral Simufilam On-Going Phase 3 Trials
25 Mar 24
(SAVA) - Analyzing Cassava Sciences's Short Interest
21 Mar 24
Alzheimer's Drug Trial Results Questioned After 'Damning' FDA Inspection Report
11 Mar 24
Boeing, Oracle, Meta Platforms, Cassava Sciences, Tesla: Why These 5 Stocks Are On Investors' Radars Today
11 Mar 24
Press releases
Redemption Date Announced for Warrants
15 Apr 24
CASSAVA ALERT: Bragar Eagel & Squire, P.C. is Investigating Cassava Sciences, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
5 Apr 24
DEADLINE TODAY: The Schall Law Firm Encourages Investors in Cassava Sciences, Inc. with Losses of $100,000 to Contact the Firm
2 Apr 24
Cassava Sciences, Inc. investors: Please contact the Portnoy Law Firm to recover your losses; April 2, 2024 deadline.
1 Apr 24
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Cassava Sciences, Inc. of Class Action Lawsuit and Upcoming Deadlines – SAVA
31 Mar 24